Frailty and Diffuse Large B-Cell Lymphoma: Where Do We Go From Here?

Author: P. Connor Johnson MD
View More View Less

Disclosures: Dr. Johnson has disclosed serving as a consultant for AstraZeneca.

Correspondence: P. Connor Johnson, MD, Division of Hematology & Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Yawkey 7B, Boston, MA 02114. Email: pcjohnson@mgh.harvard.edu

View associated content

  • 1.

    Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin 2021;71:733.

  • 2.

    Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 2016;66:443459.

  • 3.

    Khan Y, Brem EA. Considerations for the treatment of diffuse large B cell lymphoma in the elderly. Curr Hematol Malig Rep 2019;14:228238.

  • 4.

    Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460468.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Hamaker ME, Vos AG, Smorenburg CH, et al. The value of geriatric assessments in predicting treatment tolerance and all-cause mortality in older patients with cancer. Oncologist 2012;17:14391449.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Merli F, Luminari S, Tucci A, et al. Simplified Geriatric Assessment in older patients with diffuse large B-Cell lymphoma: the Prospective Elderly Project of the Fondazione Italiana Linfomi. J Clin Oncol 2021;39:12141222.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Liu MA, DuMontier C, Murillo A, et al. Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies. Blood 2019;134:374382.

  • 8.

    Fama A, Martin P, Allmer C, et al. Vulnerable Elders Survey-13 (VES-13) predicts 1-year mortality risk in newly diagnosed non-Hodgkin lymphoma (NHL). Blood 2019;134:6969.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Vijenthira A, Mozessohn L, Nagamuthu C, et al. Frailty in patients with newly diagnosed diffuse large-B-cell lymphoma receiving curative-intent therapy: a population-based study. J Natl Compr Canc Netw 2022;20:635643.e9.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Lin RJ, Owens CN, Drill E, et al. Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma. Haematologica 2022;107:11441152.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Lakshmaiah KC, Asati V, Babu KG, et al. Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B-cell lymphoma. Eur J Haematol 2018;100:644648.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 428 428 428
PDF Downloads 244 244 244
EPUB Downloads 0 0 0